Restricted accessResearch articleFirst published online 1991-6
The Exponential-Gompertzian Tumor Growth Model: Data from Six Tumor Cell Lines in Vitro and in Vivo. Estimate of the Transition point from Exponential to Gompertzian Growth and Potential Cinical Implications
The published growth data were examined for six tumor cell lines (FSA, Line 1, MCA-11, EMT6/RO, MGH-U1, MLS) grown in vivo and in vitro as monolayer cultures and as multicell spheroids cultured under different experimental conditions. Serial estimates of tumor sizes were fitted by Gompertzian equations obtained with a non-linear computerized program. When the growth equations of the same tumor growing in different experimental conditions were compared, the Gompertzian parameters α0 (initial specific growth rate) and β (retardation factor) showed a strong linear correlation in all the examined lines, with no exception. This occurrence supports the exponential-Gompertzian growth model, where an early exponential phase (which is virtually not influenced by exogenous factors) is followed by a Gompertzian phase, the characteristics of which are greatly dependent on environmental conditions. The transition between the two phases was estimated to occur when tumor size reached 102–104 cells, depending on the cell line. This kinetic change in tumor growth may be clinically relevant as regards cytotoxic treatments. It could explain some consequences of delays in adjuvant (postoperative) chemotherapy observed in clinical trials on primary breast cancer.
Get full access to this article
View all access options for this article.
References
1.
AfifiA.A., AzenS.P.: Statistical analysis: a computer oriented approach.Academic press, New York1979.
2.
AllisonD.C., AndersonS., RidolphoP.F., MeyneJ., RobertsonJ.: Alterations in the DNA metabolism of MCA-11 mouse mammary tumor cells grown in vivo ad in vitro.Cancer Res., 46: 3951–3957, 1986.
3.
BrooksR.R., JonesS.E., SalmonS.E., ChaseE.M., DavisS.L., MoonT.E., GiordanoG.F., KetchelS.J., JacksonR.A.: Improved outcome with early treatment in an adjuvant breast cancer program.Proc. Am. Soc. Clin. Oncol., 2: 110(Abs.), 1983.
4.
BubenikJ., BaresovaM., ViklickyV., JacoubkovaJ., SainerovaH., DonnerJ.: Established cell line of urinary bladder carcinoma (T24) containing tumor-specific antigen.Int. J. Cancer, 11: 765–773, 1973.
DemicheliR., ForoniR., IngrossoA., PratesiG., SoranzoC., TortoretoM.: An exponential-Gopertzian description of LoVo cell tumor growth from in vivo and in vitro data.Cancer Res., 49: 6543–6546, 1989.
7.
FisherB., GunduzN., CoyleJ., RudockC., SafferE.: Presence of a growth-stimulating factor in serum following primary tumor removal in mice.Cancer Res., 49: 1996–2001, 1989.
8.
FreyerJ.P., SutherlandR.M.: Selective dissociation and characterization of cells from different regions of multicell tumor spheroids.Cancer Res., 40: 3956–3965, 1980.
9.
FreyerJ.P., SutherlandR.M.: A reduction of the in situ rates of oxygen and glucose consumption of cells in EMT6/R0 spheroids during growth.J. Cell Physiol., 124: 516–524, 1985.
10.
FreyerJ.P., SutherlandR.M.: Regulation of growth saturation and development of necrosis in EMT6/R0 multicellular spheroids by the glucose and oxygen supply.Cancer Res., 46: 3504–3512, 1986.
11.
GlucksbergH., RivkinS.E., RasmussenS., TranumbB., Gad El MawlaN., CostanziJ., HoogstratenB., AthensJ., MaloneyT., Mc CrackenJ., VaughnC.: Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive nodes. A Southwest Oncology Group study.Cancer, 50: 423–434, 1982.
12.
KillionJ.J., FidlerI.J.: The biology of tumor metastasis.Semin. Oncol., 16: 106–115, 1989.
13.
KnukelR., HofstadterF., JenkinsW.E.A., MastersJ.R.W.: Sensitivities of monolayers and spheroids of the human bladder cancer cell line MGH-U1 to the drugs used for intravesical chemotherapy.Cancer Res., 49: 1397–1401, 1989.
14.
KoscielnyS., TubianaM., LeM.G., ValleronA.J., MouriesseH., ContessoG., SarrazinD.: Breast cancer: relationship between the size of the primary tumor and the probability of metastatic dissemination.Br. J. Cancer, 49: 709–715, 1984.
15.
KovnatA., ArmitageM., TannockI.: Xenografts of human bladder cancer in immune-deprived mice.Cancer Res., 42: 3696–3703, 1982.
16.
MansiJ.L., BergerU., McDonnelT., PopleA., RayterZ., GazetJ.C., CoombesR.C.: The fate of bone marrow micrometastases in patients with primary breast cancer.J. Clin. Oncol., 7: 445–449, 1989.
17.
MastersJ.R.W., HepburnP.J., WalkerL., HighmanW.J., TreidosiewiczL.K., PoveyS., PorkarM., HillB., RiddleP.R., FranksL.M.: Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.Cancer Res., 46: 3630–3636, 1986.
18.
NicolsonG.L.: Tumor cell instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression.Cancer Res., 47: 1473–1487, 1987.
19.
Nissen-MeyerR., HostH., KjellgrenK., ManssonB., NorinT.: Treatment of node-negative breast cancer patients with or short course of chemotherapy immediately after surgery. N.C.I.Monogr., 1: 125–128, 1986.
20.
PagetS.: The distribution of the secondary growths in cancer of the breast.Lancet, 1: 571–573, 1889.
21.
PronzatoP., AmorosoD., BestelliG., BottoF., RossoR.: Adjuvant chemotherapy in breast cancer: impact of individual dose intensity on treatment outcome.E.C.C.O. 5, Book of Abstracts, Abs P-1035, London 1989.
22.
RagazJ.: Emerging modalities for adjuvant therapy of breast cancer: neoadjuvant chemotherapy. N.C.I.Monogr., 1: 145–152, 1986.
23.
RockwellS.C., KallmanR.F., FajardoL.F.: Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative.J. Natl. Cancer Inst., 49: 735–747, 1972.
24.
RofstadE.K., SutherlandR.M.: Radiation sensitivity of human ovarian carcinoma cell lines in vitro: effects of growth factors and hormones, basement membrane ad intercellular contact.Int. J. Radiat. Oncol. Biol. Phys., 15: 921–927, 1988.
25.
RofstadE.K., SutherlandR.M.: Growth and radiation sensitivity of the MLS human ovarian carcinoma cell line grown as multicellular spheroids and xenografted tumors.Br. J. Cancer, 59: 28–35, 1989.
26.
RotinD., Steel-NorwoodD., GrinsteinS., TannockI.: Requirement of the Na+/H+ exchanger for tumor growth.Cancer Res., 49: 205–211, 1989.
27.
SpremulliE.N., DexterD.L.: Human tumor cell heterogeneity and metastasis.J. Clin. Oncol., 1: 496–506, 1983.
28.
SteelG.G.: Growth kinetics of tumors.Clarendon Press, Oxford1977.
29.
SutherlandR.M.: Cell and environment interactions in tumor microregions: the multicell spheroid model.Science, 240: 177–184, 1988.
30.
TannockI., KopelyanI.: Influence of glucose concentration on growth and formation of necrosis in spheroids derived from a human bladder cell line.Cancer Res., 46: 3105–3110, 1986.
31.
TannockI., KopelyanI.: Variation of p02 in the growth medium of spheroids: interaction with glucose to influence spheroid growth and necrosis.Br. J. Cancer, 53: 823–827, 1986.
32.
TannockI., SteelD., RobertsJ.: Influence of reduced concentration of L-glutamine on growth and viability of cells in monolayer, in spheroids and in experimental tumors Br J.Cancer, 54: 733–741, 1986.
33.
YuhasJ.M., LiA.P.: Growth fraction as the major determinant of multicellular tumor spheroid growth rates.Cancer Res., 38: 1528–1532, 1978.
34.
YuhasJ.M., LiA.P., MartinezA.O., LadmanA.J.: A simplified method for production and growth of multicellular tumor spheroids.Cancer Res., 37: 3639–3643, 1977.
35.
YuhasJ.M., PaziminhoN.H.: Inibition of subcutaneously growing Line 1 carcinomas due to metastatic spread.Cancer Res., 34: 2005–2010, 1974.
36.
YuhasJ.M., TarletonA.E., HarmanJ.G.: In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo.Cancer Res., 38: 3595–3598, 1978.
37.
YuhasJ.M., TarletonA.E., HolzenK.B.: Multicellular tumor spheroid formation by breast cancer cells isolated from different sites.Cancer Res., 38: 2486–2491, 1978.
